{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:38:58Z","timestamp":1776872338465,"version":"3.51.2"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-NR076337"],"award-info":[{"award-number":["RS-2023-NR076337"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-025-11405-2","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T06:27:18Z","timestamp":1766989638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combined treatment of TKIs with Cilengitide overcomes afatinib-resistance in EGFR-mutated NSCLC cells"],"prefix":"10.1007","volume":"53","author":[{"given":"Hye Eun","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujin","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeonsoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"11405_CR1","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1126\/science.1101637","volume":"305","author":"R Sordella","year":"2004","unstructured":"Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163\u20131167. https:\/\/doi.org\/10.1126\/science.1101637","journal-title":"Science"},{"key":"11405_CR2","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1002\/cncr.27409","volume":"118","author":"RC Doebele","year":"2012","unstructured":"Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB et al (2012) Oncogene status predicts patterns of metastatic spread in treatment-naive non-small cell lung cancer. Cancer 118:4502\u20134511. https:\/\/doi.org\/10.1002\/cncr.27409","journal-title":"Cancer"},{"key":"11405_CR3","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380\u20132388. https:\/\/doi.org\/10.1056\/NEJMoa0909530","journal-title":"N Engl J Med"},{"key":"11405_CR4","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1158\/2159-8290.CD-15-0654","volume":"5","author":"JN Gallant","year":"2015","unstructured":"Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Yelensky R et al (2015) EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to Afatinib. Cancer Discov 5:1155\u20131163. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0654","journal-title":"Cancer Discov"},{"key":"11405_CR5","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L, Carbone DP (2018) Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 29:i10\u2013i19. https:\/\/doi.org\/10.1093\/annonc\/mdx703","journal-title":"Ann Oncol"},{"key":"11405_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1158\/1535-7163.MCT-16-0407","volume":"16","author":"Y Kobayashi","year":"2017","unstructured":"Kobayashi Y, Azuma K, Nagai H, Kim YH, Sekine I (2017) Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to Afatinib in lung cancer. Mol Cancer Ther 16:357\u2013364. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0407","journal-title":"Mol Cancer Ther"},{"key":"11405_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3892\/ijo.2021.5270","volume":"59","author":"J He","year":"2021","unstructured":"He J, Huang Z, Han L, Gong Y, Xiong L, Feng W et al (2021) Mechanisms and management of 3rd generation EGFR TKI resistance in advanced non-small cell lung cancer (Review). Int J Oncol 59:90. https:\/\/doi.org\/10.3892\/ijo.2021.5270","journal-title":"Int J Oncol"},{"key":"11405_CR8","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26. https:\/\/doi.org\/10.1126\/scitranslmed.3002003","journal-title":"Sci Transl Med"},{"key":"11405_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring EGFR mutations (WJTOG3405): an open-label, randomised phase 3 trial. Lancet Oncol 11:121\u2013128. https:\/\/doi.org\/10.1016\/S1470-2045(09)70364-X","journal-title":"Lancet Oncol"},{"key":"11405_CR10","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1111\/cas.13763","volume":"109","author":"H Sato","year":"2018","unstructured":"Sato H, Yamamoto H, Sakaguchi M, Hasegawa M, Nomura M, Hijioka S et al (2018) Combined Inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. Cancer Sci 109:3183\u20133196. https:\/\/doi.org\/10.1111\/cas.13763","journal-title":"Cancer Sci"},{"key":"11405_CR11","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.cllc.2012.12.001","volume":"14","author":"SM Gadgeel","year":"2013","unstructured":"Gadgeel SM, Wozniak A (2013) Preclinical rationale for PI3K\/Akt\/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clin Lung Cancer 14:322\u2013332. https:\/\/doi.org\/10.1016\/j.cllc.2012.12.001","journal-title":"Clin Lung Cancer"},{"key":"11405_CR12","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.21037\/tcr-23-956","volume":"12","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Wang R, Xu L (2023) Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: A narrative review. Translational Cancer Res 12:3764\u20133778. https:\/\/doi.org\/10.21037\/tcr-23-956","journal-title":"Translational Cancer Res"},{"key":"11405_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.drup.2005.10.002","volume":"8","author":"K Temming","year":"2005","unstructured":"Temming K, Schiffelers RM, Molema G, Kok RJ (2005) RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updates 8:381\u2013402. https:\/\/doi.org\/10.1016\/j.drup.2005.10.002","journal-title":"Drug Resist Updates"},{"key":"11405_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.canlet.2018.12.021","volume":"446","author":"F Bianchini","year":"2019","unstructured":"Bianchini F, Portioli E, Ferlenghi F, Baldini N, Caruso A, Tesei A et al (2019) Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma. Cancer Lett 446:25\u201337. https:\/\/doi.org\/10.1016\/j.canlet.2018.12.021","journal-title":"Cancer Lett"},{"key":"11405_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/cancers11040531","volume":"11","author":"A Sartori","year":"2019","unstructured":"Sartori A, Corno C, De Cesare M, Amboldi N, Ciarrocchi A, Belotti D et al (2019) Efficacy of a selective binder of \u03b1v\u03b23 integrin linked to the tyrosine kinase inhibitor Sunitinib in ovarian carcinoma preclinical models. Cancers 11:531. https:\/\/doi.org\/10.3390\/cancers11040531","journal-title":"Cancers"},{"key":"11405_CR16","doi-asserted-by":"publisher","first-page":"e6800","DOI":"10.1002\/cam4.6800","volume":"3","author":"H Javid","year":"2024","unstructured":"Javid H, Oryani MA, Rezagholinejad N, Tabrizi M, Yousefi M, Jadidi-Niaragh F et al (2024) RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions. Cancer Med 3:e6800. https:\/\/doi.org\/10.1002\/cam4.6800","journal-title":"Cancer Med"},{"key":"11405_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2174\/187152010794728639","volume":"10","author":"C Mas-Moruno","year":"2010","unstructured":"Mas-Moruno C, Rechenmacher F, Kessler H (2010) Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anti-cancer Agents Med Chem 10:753\u2013768. https:\/\/doi.org\/10.2174\/187152010794728639","journal-title":"Anti-cancer Agents Med Chem"},{"key":"11405_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2217\/fon.11.8","volume":"7","author":"DA Reardon","year":"2011","unstructured":"Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R et al (2011) Cilengitide: an RGD pentapeptide \u03b1v\u03b23 and \u03b1v\u03b25 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol 7:339\u2013354. https:\/\/doi.org\/10.2217\/fon.11.8","journal-title":"Future Oncol"},{"key":"11405_CR19","doi-asserted-by":"publisher","first-page":"127039","DOI":"10.1016\/j.bmcl.2020.127039","volume":"30","author":"CL Meena","year":"2020","unstructured":"Meena CL, Singh D, Weinm\u00fcller M, Rechenmacher F, Kessler H (2020) Novel cilengitide-based Cyclic RGD peptides as \u03b1v\u03b23 integrin inhibitors. Bioorg Med Chem Lett 30:127039. https:\/\/doi.org\/10.1016\/j.bmcl.2020.127039","journal-title":"Bioorg Med Chem Lett"},{"key":"11405_CR20","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.2147\/IJN.S26670","volume":"6","author":"LL Cai","year":"2011","unstructured":"Cai LL, Liu P, Li X, Tan YF, Jin Q, Ren J (2011) RGD peptide-mediated chitosan-based polymeric micelles targeting delivery for integrin-overexpressing tumor cells. Int J Nanomed 6:3499\u20133508. https:\/\/doi.org\/10.2147\/IJN.S26670","journal-title":"Int J Nanomed"},{"key":"11405_CR21","doi-asserted-by":"publisher","first-page":"e0232917","DOI":"10.1371\/journal.pone.0232917","volume":"15","author":"KY Park","year":"2020","unstructured":"Park KY, Kim J (2020) Cyclic pentapeptide cRGDfK enhances the inhibitory effect of Sunitinib on TGF-\u03b21-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells. PLoS ONE 15:e0232917. https:\/\/doi.org\/10.1371\/journal.pone.0232917","journal-title":"PLoS ONE"},{"key":"11405_CR22","doi-asserted-by":"publisher","first-page":"639095","DOI":"10.3389\/fphar.2021.639095","volume":"12","author":"J Jeong","year":"2021","unstructured":"Jeong J, Kim J (2021) Cyclic RGD pentapeptide Cilengitide enhances efficacy of gefitinib on TGF-\u03b21-induced epithelial-to-mesenchymal transition and invasion in human non-small cell lung cancer cells. Front Pharmacol 12:639095. https:\/\/doi.org\/10.3389\/fphar.2021.639095","journal-title":"Front Pharmacol"},{"key":"11405_CR23","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.3390\/ijms23073423","volume":"23","author":"J Jeong","year":"2022","unstructured":"Jeong J, Kim J (2022) Combination effect of Cilengitide with erlotinib on TGF-\u03b21-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells. Int J Mol Sci 23:3423. https:\/\/doi.org\/10.3390\/ijms23073423","journal-title":"Int J Mol Sci"},{"key":"11405_CR24","doi-asserted-by":"publisher","first-page":"e24285","DOI":"10.1002\/pep2.24285","volume":"114","author":"KY Park","year":"2022","unstructured":"Park KY, Jeong J, Kim J (2022) Synthesis and biological evaluation of Cilengitide derivatives on TGF-\u03b21-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells. Pept Sci 114:e24285. https:\/\/doi.org\/10.1002\/pep2.24285","journal-title":"Pept Sci"},{"key":"11405_CR25","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/bkcs.12601","volume":"43","author":"M Seo","year":"2022","unstructured":"Seo M, Kim J (2022) Combination effect of Cilengitide derivatives with gefitinib on TGF-\u03b21-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells. Bull Korean Chem Soc 43:1212\u20131216. https:\/\/doi.org\/10.1002\/bkcs.12601","journal-title":"Bull Korean Chem Soc"},{"key":"11405_CR26","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871\u2013890. https:\/\/doi.org\/10.1016\/j.cell.2009.11.007","journal-title":"Cell"},{"key":"11405_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bbcan.2018.10.003","volume":"1871","author":"E Tulchinsky","year":"2019","unstructured":"Tulchinsky E, Demidov O, Kriajevska M, Barlev NA (2019) EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer. Biochim Et Biophys Acta Reviews Cancer 1871:29\u201339. https:\/\/doi.org\/10.1016\/j.bbcan.2018.10.003","journal-title":"Biochim Et Biophys Acta Reviews Cancer"},{"key":"11405_CR28","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10555-012-9375-7","volume":"31","author":"Y Drabsch","year":"2012","unstructured":"Drabsch Y, ten Dijke P (2012) TGF-\u03b2 signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev 31:553\u2013568. https:\/\/doi.org\/10.1007\/s10555-012-9375-7","journal-title":"Cancer Metastasis Rev"},{"key":"11405_CR29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.21037\/tlcr.2016.04.07","volume":"5","author":"KR Jakobsen","year":"2016","unstructured":"Jakobsen KR, Demuth C, Sorensen BS, Frederiksen CM, Hansen LL, Kristensen LS (2016) The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Translational Lung Cancer Res 5:172\u2013182. https:\/\/doi.org\/10.21037\/tlcr.2016.04.07","journal-title":"Translational Lung Cancer Res"},{"key":"11405_CR30","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1101\/gad.1350705","volume":"19","author":"J Massagu\u00e9","year":"2005","unstructured":"Massagu\u00e9 J, Seoane J, Wotton D (2005) Smad transcription factors. Genes Dev 19:2783\u20132810. https:\/\/doi.org\/10.1101\/gad.1350705","journal-title":"Genes Dev"},{"key":"11405_CR31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/37284","volume":"390","author":"CH Heldin","year":"1997","unstructured":"Heldin CH, Miyazono K, ten Dijke P (1997) TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390:465\u2013471. https:\/\/doi.org\/10.1038\/37284","journal-title":"Nature"},{"key":"11405_CR32","doi-asserted-by":"publisher","first-page":"1277199","DOI":"10.3389\/fphar.2023.1277199","volume":"14","author":"Y Seo","year":"2023","unstructured":"Seo Y, Seo M, Kim J (2023) Effects of Cilengitide derivatives on TGF-\u03b21-induced epithelial-to-mesenchymal transition and invasion in gefitinib-resistant non-small cell lung cancer cells. Front Pharmacol 14:1277199. https:\/\/doi.org\/10.3389\/fphar.2023.1277199","journal-title":"Front Pharmacol"},{"key":"11405_CR33","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1158\/0008-5472.CAN-12-4136","volume":"73","author":"K Shien","year":"2013","unstructured":"Shien K, Toyooka S, Yamamoto H, Soh J, Jida M, Thu KL et al (2013) Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res 73:3051\u20133061. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-4136","journal-title":"Cancer Res"},{"key":"11405_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2013 delta delta C(T)) method. Methods 25:402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.1262","journal-title":"Methods"},{"key":"11405_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27\u201355. https:\/\/doi.org\/10.1016\/0065-2571(84)90007-4","journal-title":"Adv Enzyme Regul"},{"key":"11405_CR36","doi-asserted-by":"publisher","first-page":"7994","DOI":"10.1158\/1078-0432.CCR-04-1087","volume":"10","author":"L Zhao","year":"2004","unstructured":"Zhao L, Wientjes MG, Au JL (2004) Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 10:7994\u20138004. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1087","journal-title":"Clin Cancer Res"},{"key":"11405_CR37","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s11307-022-01782-6","volume":"25","author":"C Ghezzi","year":"2023","unstructured":"Ghezzi C, Perez S, Ryan K, Putluri N, Gardner A, Hu J et al (2023) Early reduction of glucose consumption is a biomarker of kinase inhibitor efficacy which can be reversed with GLUT1 overexpression in lung cancer cells. Mol Imaging Biology 25:541\u2013553. https:\/\/doi.org\/10.1007\/s11307-022-01782-6","journal-title":"Mol Imaging Biology"},{"key":"11405_CR38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nrc727","volume":"2","author":"JD Hood","year":"2002","unstructured":"Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91\u2013100. https:\/\/doi.org\/10.1038\/nrc727","journal-title":"Nat Rev Cancer"},{"key":"11405_CR39","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","volume":"5","author":"L Huang","year":"2015","unstructured":"Huang L, Fu L (2015) Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sinica B 5:390\u2013401. https:\/\/doi.org\/10.1016\/j.apsb.2015.07.001","journal-title":"Acta Pharm Sinica B"},{"key":"11405_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1152\/physrev.1993.73.1.161","volume":"73","author":"P Mignatti","year":"1993","unstructured":"Mignatti P, Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161\u2013195. https:\/\/doi.org\/10.1152\/physrev.1993.73.1.161","journal-title":"Physiol Rev"},{"key":"11405_CR41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1073\/pnas.98.1.119","volume":"98","author":"S Silletti","year":"2001","unstructured":"Silletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA (2001) Disruption of matrix metalloproteinase 2 binding to integrin \u03b1v\u03b23 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA 98:119\u2013124. https:\/\/doi.org\/10.1073\/pnas.98.1.119","journal-title":"Proc Natl Acad Sci USA"},{"key":"11405_CR42","first-page":"8730","volume":"61","author":"L Bello","year":"2001","unstructured":"Bello L, Lucini V, Carrabba G, Giussani C, Machold R, Forloni GL et al (2001) Simultaneous Inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2. Cancer Res 61:8730\u20138736","journal-title":"Cancer Res"},{"key":"11405_CR43","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1126\/science.1183057","volume":"328","author":"KN Sugahara","year":"2010","unstructured":"Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR et al (2010) Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328:1031\u20131035. https:\/\/doi.org\/10.1126\/science.1183057","journal-title":"Science"},{"key":"11405_CR44","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.3390\/cells10112908","volume":"10","author":"CM Li","year":"2021","unstructured":"Li CM, Haratipour P, Lingeman RG, Zhang K, Rajapakse VN, Tang Y et al (2021) Novel peptide therapeutic approaches for cancer treatment. Cells 10:2908. https:\/\/doi.org\/10.3390\/cells10112908","journal-title":"Cells"},{"key":"11405_CR45","doi-asserted-by":"publisher","first-page":"e17841","DOI":"10.1016\/j.heliyon.2023.e17841","volume":"9","author":"DY Guo","year":"2023","unstructured":"Guo DY, Chen ZH, Fu YF, Zhang Y, Zhang T, Hu CY et al (2023) Cilengitide inhibits osteoclast adhesion through blocking the \u03b1v\u03b23-mediated FAK\/Src signaling pathway. Heliyon 9:e17841. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17841","journal-title":"Heliyon"},{"key":"11405_CR46","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1080\/21655979.2022.2029236","volume":"13","author":"X Pan","year":"2022","unstructured":"Pan X, Yi M, Liu C, Liu D, Wu K (2022) Cilengitide, an \u03b1v\u03b23-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model. Bioengineered 13:4557\u20134572. https:\/\/doi.org\/10.1080\/21655979.2022.2029236","journal-title":"Bioengineered"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11405-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11405-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11405-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T06:27:20Z","timestamp":1766989640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11405-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11405"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11405-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No animals were used in this study. Experiments were performed using previously established cell lines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"233"}}